16/06/2022

Press release

YSIOS CAPITAL APPOINTS WEN WEN CHENG AS HEAD OF LEGAL.

 

 

 

 

 

 

 

 

− Wen Wen Cheng joins Ysios Capital as Head of Legal after 10 years at Cuatrecasas, Barcelona.
− This addition will strengthen the Ysios Capital team by incorporating an expert in legal matters.

SAN SEBASTIÁN/BARCELONA, June 16, 2022– Ysios Capital, a European life sciences venture capital firm, today announced that it has appointed Wen Wen Cheng as Head of Legal.

Wen Wen will be responsible for the legal matters relating to the management company, funds, and portfolio companies. Her knowledge and experience will be key in all stages of the investment process from the negotiation of letters of intent and shareholders’ agreements to all legal aspects of the divestment process. In her role as Head of Legal, she will also ensure the accomplishment of the anti-money laundering regulations and will manage the communication with regulatory entities.

Wen Wen holds a degree in Law and a degree in Business Administration and Management, both from Pompeu Fabra University in Barcelona. She joined Cuatrecasas in 2012, where she practiced as a lawyer specializing in corporate law, mergers and acquisitions, and real estate transactions until joining Ysios.
«We are delighted to incorporate a specialized legal profile such as Wen Wen’s, who will undoubtedly add a great value to the process of negotiating investment and divestment contracts, as well as in other legal matters of the firm. We believe that it is the moment to strengthen this area of the company and take a step forward in our growth plan» comments Julia Salaverria, Managing Partner of Ysios Capital.

“Ysios Capital is a strong player in the European biotech sector with an experienced and diverse team committed to innovation, and I look forward to contributing to the growth of this promising sector” comments Wen Wen Cheng, head of Legal of Ysios Capital.

Ysios Capital has recently participated in Minoryx’s financing round and has added the first US company to Ysios BioFund III’s portfolio, Mineralys Therapeutics. Ysios is now focused on managing its portfolio companies and expects to close up to two new investments before year-end.

About Ysios Capital

Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and midstage, highly innovative life science companies bringing life-changing treatments to patients, with a focus on indications with high unmet need. Our diverse international team in San Sebastián and Barcelona is driven by science, with the ambition to transform capital into medical breakthroughs. Ysios Capital was founded in 2008 and has over $450 million in assets under management through its three funds.

For more information, please visit www.ysioscapital.com

Nuevos informes, publicaciones y series de datos: El Capital riesgo Informal en España 2022 / Informe de Impacto Económico y Social de los préstamos otorgados por Enisa / Suscríbete a la newsletter con las noticias destacadas de cada semana / Serie de datos (excel) de Grupos-Redes Business Angels, aceleradoras-incubadoras. 2021

Webcapitalriesgo.com está patrocinada por Quantum Capital Partners

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos requeridos están marcados *

Publicar comentario